RU2016142510A - Соединения и способы для транс-мембранной доставки молекул - Google Patents
Соединения и способы для транс-мембранной доставки молекул Download PDFInfo
- Publication number
- RU2016142510A RU2016142510A RU2016142510A RU2016142510A RU2016142510A RU 2016142510 A RU2016142510 A RU 2016142510A RU 2016142510 A RU2016142510 A RU 2016142510A RU 2016142510 A RU2016142510 A RU 2016142510A RU 2016142510 A RU2016142510 A RU 2016142510A
- Authority
- RU
- Russia
- Prior art keywords
- drug
- conjugate
- disease
- fragment
- membrane
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims 19
- 238000000034 method Methods 0.000 title claims 10
- 150000001875 compounds Chemical class 0.000 title claims 7
- 239000003814 drug Substances 0.000 claims 20
- 229940079593 drug Drugs 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 14
- 239000000126 substance Substances 0.000 claims 9
- -1 fluorine Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000005684 electric field Effects 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- 238000012377 drug delivery Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 150000003431 steroids Chemical group 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000033116 oxidation-reduction process Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 238000005192 partition Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 150000007970 thio esters Chemical class 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
Claims (59)
1. Применение ассиметрично полярного химического фрагмента, способного перемещаться в пределах микросреды гидрофобной мембраны по направлению к мембранному ядру, который направляется электрическим полем внутренней мембраны, для доставки лекарственного средства через биологическую мембрану.
2. Способ доставки лекарственного средства через биологическую мембрану, где способ включает:
конъюгирование, по меньшей мере, одного ассиметрично полярного химического фрагмента с лекарственным средством, где фрагмент способен перемещаться в пределах микросреды гидрофобной мембраны по направлению к мембранному ядру, который направляется электрическим полем внутренней мембраны; и
контактирование биологической мембраны с конъюгированным лекарственным средством.
3. Способ доставки лекарственного средства через биологическую мембрану, где способ включает:
обеспечение конъюгата лекарственного средства и, по меньшей мере, одного ассиметрично полярного химического фрагмента, где фрагмент способен перемещаться в пределах микросреды гидрофобной мембраны по направлению к мембранному ядру, который направляется электрическим полем внутренней мембраны; и
контактирование биологической мембраны с конъюгированным лекарственным средством.
4. Конъюгат лекарственного средства и, по меньшей мере, одного ассиметрично полярного химического фрагмента, где фрагмент способен перемещаться в пределах микросреды гидрофобной мембраны по направлению к мембранному ядру, который направляется электрическим полем внутренней мембраны, для применения в доставке лекарственного средства через биологическую мембрану.
5. Применение, или способ, или конъюгат для применения в соответствии с каким-либо из предшествующих пунктов, где ассиметрично полярный химический фрагмент имеет коэффициент распределения октанол/вода >1.
6. Применение, или способ, или конъюгат для применения в соответствии с каким-либо из предшествующих пунктов, где ассиметрично полярный химический фрагмент содержит сфокусированный отрицательный полюс, содержащий, по меньшей
мере, один электроотрицательный атом, и рассредоточенный положительный полюс.
7. Применение, или способ, или конъюгат для применения по п. 6, где
отрицательный полюс содержит, по меньшей мере, один электроотрицательный атом, выбранный из галогена, такого как фтор, или кислорода; и/или
положительный полюс содержит углеводородную(ые) цепь(и), стероидный фрагмент или их комбинации, необязательно замещенные электроположительными атомами, выбранными из кремния, бора, фосфора и серы.
8. Применение, или способ, или конъюгат для применения в соответствии с каким-либо из предшествующих пунктов, где ассиметрично полярный химический фрагмент представляет собой соединение, имеющее структуру формулу (II), как определено в каком-либо одном из пп. 13 или 14.
9. Применение, или способ, или конъюгат для применения в соответствии с каким-либо из предшествующих пунктов, где лекарственное средство представляет собой низкомолекулярное лекарственное средство или макромолекулу лекарственного средства, выбранный из встречающихся в природе или модифицированных РНК или ДНК, малых интерферирующих РНК (миРНК), антисмыслового олигонуклеотида (ASO) или терапевтического белка,
необязательно где терапевтический белок содержит CRISPR белок, такой как белок Cas9, или
где лекарственное средство содержит дайсер субстрат, содержащий двухцепочечную РНК из 25-30 нуклеотидов, который включает последовательность для подавления экспрессии гена-мишени.
10. Конъюгат лекарственного средства и, по меньшей мере, одного ассиметрично полярного химического фрагмента, как определено в каком-либо одном из пп. 3-9, для применения в медицине.
11. Конъюгат лекарственного средства и, по меньшей мере, одного ассиметрично полярного химического фрагмента, как определено в каком-либо одном из пп. 3-9, для применения в лечении заболеваний, где лекарственное средство является приемлемым в лечении заболевания.
12. Конъюгат для применения по п. 11, где заболевание представляет собой рак, токсический инсульт, ишемическое заболевание, инфекционное заболевание, болезнь депонирования белка, травму, иммуноопосредованное заболевание, или
дегенеративное заболевание, или нейродегенеративное заболевание, такое как болезнь Альцгеймера, болезнь двигательных нейронов, болезнь Паркинсона, болезнь Хантингтона, рассеянный склероз и болезнь Крейтцфельда-Якоба.
13. Соединение для трансмембранной доставки лекарственного средства, где соединение соответствует формуле (II):
в которой
а представляет собой целое число 1, 2, 3 или 4
А выбирают из структур, которые представлены формулами (III), (IV) и (V):
в которой
М выбирают из -О- или -СН2-; и
g и h независимо представляют собой целое число, выбранное из 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 и 16;
В представляет собой насыщенный или частично насыщенный линейный, разветвленный или циклический С1, С2, С3, С4, С5, С6, С7, С8, С9, С10, С11, C12, C13, С14, C15, C16, C17, C18, С19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42 алкил, алкилен, гетероалкилен, арил, гетероарил; стероид или их комбинацию;
Q отсутствует или выбирают из сложного эфира, тио-сложного эфира, амида, карбамата, дисульфида [-(S-S)-], простого эфира [-O-], рН-чувствительного фрагмента, и чувствительного к окислению-восстановлению фрагмента; и
L отсутствует или необязательно представляет собой замещенный линейный, циклический или разветвленный, насыщенный, ненасыщенный или частично насыщенный C1, С2, С3, С4, С5, С6, С7, С8, С9, С10, С11, С12, С13, С14, С15, С16, С17, С18, С19, С20, С21, С22, С23, С24, С25, С26, С27, С28, С29, С30, С31, С32, С33, С34, С35, С36, С37, С38, С39, С40, С41, С42 алкил, алкилен, гетероалкилен, арил, гетероарил; стероид или -(O-СН2-СН2)u-, где u представляет собой целое число 1, 2, 3, 4, 5, 6, 7, 8, 9, 10; или их комбинации;
где соединение способно связываться с лекарственным средством.
14. Соединение по п. 13, имеющее структуру как представлено в формуле (VI):
в которой
n и m представляют собой целые числа, каждый независимо выбранный из нуля и 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 или 20;
k представляет собой целое число, выбранное из 2, 3, 4, 5, 6 или 7; и
Z отсутствует или выбирают из карбамата и -S-S-; и
Q представляет собой точку связывания с лекарственным средством;
или имеющее структуру как представлено в формуле (VII):
или имеющее структуру как представлено в формуле (VIIa):
или имеющее структуру как представлено в формуле (VIII):
в которой
n и m представляют собой целые числа, каждый независимо выбранный из нуля и 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 или 20;
Z отсутствует или выбирают из -S-S- или карбамата; и
Q представляет собой точку связывания с лекарственным средством;
или имеющее структуру как представлено в формуле (IX):
или имеющее структуру как представлено в формуле (IXa):
или его фармацевтически приемлемая соль, гидрат, сольват или хелат металла.
15. Конъюгат, содержащий соединение по какому-либо одному из пп. 13 или 14, связанное с лекарственным средством, в которой, необязательно, лекарственное средство является таким, как определено в п. 9.
16. Фармацевтическая композиция, содержащая конъюгат по п. 15, и фармацевтически приемлемую соль или носитель.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461971548P | 2014-03-28 | 2014-03-28 | |
US61/971,548 | 2014-03-28 | ||
US201461978903P | 2014-04-13 | 2014-04-13 | |
US61/978,903 | 2014-04-13 | ||
US201462002870P | 2014-05-25 | 2014-05-25 | |
US62/002,870 | 2014-05-25 | ||
US201462008509P | 2014-06-06 | 2014-06-06 | |
US62/008,509 | 2014-06-06 | ||
US201462091551P | 2014-12-14 | 2014-12-14 | |
US62/091,551 | 2014-12-14 | ||
PCT/IL2015/000019 WO2015145417A1 (en) | 2014-03-28 | 2015-03-29 | Compounds and methods for trans-membrane delivery of molecules |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2016142510A true RU2016142510A (ru) | 2018-05-03 |
RU2016142510A3 RU2016142510A3 (ru) | 2019-02-20 |
RU2703416C2 RU2703416C2 (ru) | 2019-10-16 |
Family
ID=54194063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016142510A RU2703416C2 (ru) | 2014-03-28 | 2015-03-29 | Соединения для транс-мембранной доставки молекул |
Country Status (12)
Country | Link |
---|---|
US (1) | US9687556B2 (ru) |
EP (1) | EP3125946B1 (ru) |
JP (1) | JP6669719B2 (ru) |
KR (1) | KR20160138210A (ru) |
CN (1) | CN106456804B (ru) |
AU (1) | AU2015237746B2 (ru) |
BR (1) | BR112016022553A2 (ru) |
CA (1) | CA2944141C (ru) |
IL (1) | IL248067B (ru) |
MX (1) | MX2016012716A (ru) |
RU (1) | RU2703416C2 (ru) |
WO (1) | WO2015145417A1 (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
US9993563B2 (en) | 2014-03-28 | 2018-06-12 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
US11318206B2 (en) | 2014-03-28 | 2022-05-03 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
JP7067793B2 (ja) | 2015-10-23 | 2022-05-16 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基編集因子およびその使用 |
KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
JP7348064B2 (ja) * | 2017-01-09 | 2023-09-20 | アポセンス リミテッド | 分子を経膜送達するための化合物及び方法 |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
US10195286B2 (en) * | 2017-07-04 | 2019-02-05 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
US11236334B2 (en) | 2017-08-22 | 2022-02-01 | National University Corporation Nagoya University | Modified polynucleotide |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
JP2021500036A (ja) | 2017-10-16 | 2021-01-07 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | アデノシン塩基編集因子の使用 |
JP2021509406A (ja) * | 2018-01-01 | 2021-03-25 | アポセンス リミテッドAposense Ltd. | 分子の膜貫通送達のための化合物および方法 |
AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
BR112022022603A2 (pt) | 2020-05-08 | 2023-01-17 | Broad Inst Inc | Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla |
EP4062942A1 (en) | 2021-03-22 | 2022-09-28 | Ludwig-Maximilians-Universität München | Disulfide-based prodrug compounds |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0935415B1 (en) * | 1996-05-01 | 2006-11-22 | Imarx Pharmaceutical Corp. | In vitro methods for delivering nucleic acids into a cell |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
AU6974798A (en) * | 1997-05-06 | 1998-11-27 | Imarx Pharmaceutical Corp. | Novel prodrugs comprising fluorinated amphiphiles |
FR2846969A1 (fr) * | 2002-11-08 | 2004-05-14 | Salles Jean Pierre | Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical |
SE527131C2 (sv) * | 2004-02-13 | 2005-12-27 | Innoventus Project Ab | Steroider för cancerbehandling |
ES2383901T5 (es) * | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
EP2064223B1 (en) | 2006-09-22 | 2013-04-24 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
KR101661636B1 (ko) * | 2008-05-13 | 2016-09-30 | 유니버시티 오브 워싱톤 | 세포로의 전달을 위한 이블록 공중합체 및 그의 폴리뉴클레오티드 복합체 |
WO2009155335A2 (en) * | 2008-06-19 | 2009-12-23 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization |
WO2010033246A1 (en) * | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
GB201122458D0 (en) * | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
MA37663B1 (fr) * | 2012-05-25 | 2019-12-31 | Univ California | Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn |
MX2014014650A (es) * | 2012-05-30 | 2015-10-14 | Univ Washington | Minivectores superenrollados como una herramienta para la reparacion, alteración y reemplazo de ácido desoxirribonucleico. |
US20160002159A1 (en) * | 2013-02-13 | 2016-01-07 | Neal ZONDLO | Perfluoro-tert-butyl hydroxyproline |
JP6486955B2 (ja) | 2013-11-18 | 2019-03-20 | アークトゥルス セラピューティクス, インコーポレイテッド | Rna送達のためのイオン化可能なカチオン性脂質 |
-
2015
- 2015-03-29 AU AU2015237746A patent/AU2015237746B2/en active Active
- 2015-03-29 JP JP2017501533A patent/JP6669719B2/ja active Active
- 2015-03-29 CN CN201580027762.3A patent/CN106456804B/zh active Active
- 2015-03-29 RU RU2016142510A patent/RU2703416C2/ru active
- 2015-03-29 MX MX2016012716A patent/MX2016012716A/es unknown
- 2015-03-29 WO PCT/IL2015/000019 patent/WO2015145417A1/en active Application Filing
- 2015-03-29 EP EP15770224.2A patent/EP3125946B1/en active Active
- 2015-03-29 BR BR112016022553A patent/BR112016022553A2/pt not_active Application Discontinuation
- 2015-03-29 KR KR1020167029764A patent/KR20160138210A/ko unknown
- 2015-03-29 CA CA2944141A patent/CA2944141C/en active Active
- 2015-08-20 US US14/830,799 patent/US9687556B2/en active Active
-
2016
- 2016-09-27 IL IL248067A patent/IL248067B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2944141C (en) | 2023-03-28 |
WO2015145417A1 (en) | 2015-10-01 |
EP3125946B1 (en) | 2022-12-07 |
CN106456804A (zh) | 2017-02-22 |
EP3125946A1 (en) | 2017-02-08 |
AU2015237746B2 (en) | 2020-01-30 |
US20160106855A1 (en) | 2016-04-21 |
US9687556B2 (en) | 2017-06-27 |
CA2944141A1 (en) | 2015-10-01 |
CN106456804B (zh) | 2020-03-17 |
MX2016012716A (es) | 2017-08-16 |
JP2017509710A (ja) | 2017-04-06 |
BR112016022553A2 (pt) | 2017-08-15 |
KR20160138210A (ko) | 2016-12-02 |
RU2703416C2 (ru) | 2019-10-16 |
RU2016142510A3 (ru) | 2019-02-20 |
IL248067A0 (en) | 2016-11-30 |
AU2015237746A1 (en) | 2016-11-03 |
IL248067B (en) | 2020-10-29 |
JP6669719B2 (ja) | 2020-03-18 |
EP3125946A4 (en) | 2017-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016142510A (ru) | Соединения и способы для транс-мембранной доставки молекул | |
JP2013138681A5 (ru) | ||
JP2017511321A5 (ru) | ||
JP2018519285A5 (ru) | ||
JP2020503049A5 (ru) | ||
CY1120685T1 (el) | Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47 | |
IL275567B1 (en) | Lipid nanoparticle comprising nucleic acid and its use | |
RU2015121940A (ru) | Альтернативные применения эффекторов сборки вируса гепатита в (hbv) | |
RU2011150787A (ru) | КОНЪЮГАТ миРНК И СПОСОБ ЕГО ПОЛУЧЕНИЯ | |
JP2016503799A5 (ru) | ||
Fuentes-Paniagua et al. | Thiol-ene synthesis of cationic carbosilane dendrons: a new family of synthons | |
Sánchez-Nieves et al. | Amphiphilic cationic carbosilane–PEG dendrimers: synthesis and applications in gene therapy | |
JP2015531789A5 (ru) | ||
EA200900154A1 (ru) | Фосфинатные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусного гепатита с с ее помощью, терапевтическое средство на их основе и названные соединения для изготовления лекарства от вирусного гепатита с | |
RU2013134746A (ru) | Низкомолекулярные конъюгаты для внутриклеточной доставки биологически активных соединений | |
JP2014529328A5 (ru) | ||
JP2013510561A5 (ru) | ||
RU2487124C2 (ru) | Новое амидное производное и его использование в качестве лекарственного средства | |
EP2177556A3 (en) | Silicone for preparing ophthalmic devices | |
MX356028B (es) | Compuesto adyuvante. | |
EA034605B1 (ru) | Новые лиганды rig-i и способы их получения | |
WO2015093495A1 (ja) | TGF-β1遺伝子発現制御のための一本鎖核酸分子 | |
JP2020514299A5 (ru) | ||
JP2013540841A5 (ru) | ||
JP6784932B2 (ja) | 生体機能性分子または薬物キャリアの化学修飾用生分解性ポリエチレングリコール誘導体 |